BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

Clinical trial NCT06773910 · RECRUITING

Trial details

NCT number: NCT06773910
Sponsor: SCRI Development Innovations, LLC
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Limited Stage Small Cell Lung Cancer

Start date: 2025-03-11
Primary completion: 2032-05-01
Enrollment: 250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.